Recent advances in managing gastrointestinal stromal tumor [version 1; referees: 2 approved] by Florence Duffaud, Axel Le Cesne

Get full text

LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy by Rebecca Ibrahim, Khalil Saleh, Claude Chahine, Rita Khoury, Nadine Khalife, Axel Le Cesne

Get full text

Overview of the role of liquid biopsy in cancer management by Tarek Assi, Rita Khoury, Rebecca Ibrahim, Maria Baz, Tony Ibrahim, Axel LE Cesne

Get full text

Targeting the VEGF Pathway in Osteosarcoma by Tarek Assi, Sarah Watson, Bachar Samra, Elie Rassy, Axel Le Cesne, Antoine Italiano, Olivier Mir

Get full text

Primitive Neuroectodermal Tumor of the Cervix Uteri by Zineb Benbrahim, Christine Haie-Meder, Pierre Duvillard, Omar El Mesbahi, Axel Le Cesne, Patricia Pautier

Get full text

Primitive Neuroectodermal Tumor of the Cervix Uteri: A case report and review of literature by Zineb Benbrahim, Christine Haie-Meder, Pierre Duvillard, Omar El-Mesbahi, Axel Le-Cesne, Patricia Pautier

Get full text

Chemotherapy in the management of periosteal osteosarcoma: A narrative review by Tarek Assi, Joseph Kattan, Hussein Nassereddine, Elie Rassy, Sylvain Briand, Charles Court, Benjamin Verret, Axel Le Cesne, Olivier Mir

Get full text

PARP1 expression in soft tissue sarcomas is a poor‐prognosis factor and a new potential therapeutic target by François Bertucci, Pascal Finetti, Audrey Monneur, Delphine Perrot, Christine Chevreau, Axel Le Cesne, Jean‐Yves Blay, Olivier Mir, Daniel Birnbaum

Get full text

Handling missing covariates in observational studies: an illustration with the assessment of prognostic factors of survival outcomes in soft-tissue or visceral sarcomas in irradiat... by Noémie Huchet, Nicolas Penel, Sylvie Bonvalot, Juliette Thariat, Françoise Ducimetière, Antoine Giraud, Maud Toulmonde, Axel Le Cesne, Jean-Yves Blay, Carine Bellera

Get full text

PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas by François Bertucci, Pascal Finetti, Delphine Perrot, Agnès Leroux, Françoise Collin, Axel Le Cesne, Jean-Michel Coindre, Jean-Yves Blay, Daniel Birnbaum, Emilie Mamessier

Get full text

Quality of Sarcoma Care: Longitudinal Real-Time Assessment and Evidence Analytics of Quality Indicators by Philip Heesen, Gabriela Studer, Beata Bode, Hubi Windegger, Benjamin Staeheli, Paul Aliu, Javier Martin-Broto, Alessandro Gronchi, Jean-Yves Blay, Axel Le Cesne, Bruno Fuchs

Get full text

Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study by Thomas Brodowicz, Bernadette Liegl-Atzwanger, Nicolas Penel, Olivier Mir, Jean-Yves Blay, Karl Kashofer, Axel Le Cesne, Emilie Decoupigny, Jennifer Wallet, Rainer Hamacher, Marie-Cecile Le Deley

Get full text

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses by Axel Le Cesne, Sebastian Bauer, George D. Demetri, Guangyang Han, Luca Dezzani, Qasim Ahmad, Jean-Yves Blay, Ian Judson, Patrick Schöffski, Massimo Aglietta, Peter Hohenberger, Hans Gelderblom

Get full text

Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature by Deborah van de Wal, Mai Elie, Axel Le Cesne, Elena Fumagalli, Dide den Hollander, Robin L. Jones, Gloria Marquina, Neeltje Steeghs, Winette T. A. van der Graaf, Olga Husson

Get full text

Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature by Jean-Yves Blay, Antoine Italiano, Axel Le Cesne, Olivier Mir, Davide Bedognetti, Michele Ceccarelli, Pascal Finetti, Daniel Birnbaum, Francois Bertucci, Emilie Mamessier, Vincent Niziers, Alexandre de Nonneville, Léna Mescam

Get full text

Prospective evaluation of intensity-modulated radiotherapy toxicity in extremity soft tissue sarcomas patients: A role for irradiated healthy soft tissue volume? by Rémi Bourdais, Samir Achkar, Charles Honoré, Matthieu Faron, Andrea Cavalcanti, Guillaume Auzac, Carine Ngo, Leila Haddag-Miliani, Benjamin Verret, Sarah Dumont, Eric Deutsch, Axel Le Cesne, Olivier Mir, Cécile Le Péchoux, Antonin Levy

Get full text

<i>TP53</i> Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials by Elise F. Nassif, Edouard Auclin, Rastilav Bahleda, Charles Honoré, Olivier Mir, Sarah Dumont, Benoite Mery, Khalil Hodroj, Mehdi Brahmi, Olivier Trédan, Isabelle Ray-Coquard, Jean-Yves Blay, Christophe Massard, Axel Le Cesne, Armelle Dufresne

Get full text

TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma by Joonil Jung, Joon Sang Lee, Mark A. Dickson, Gary K. Schwartz, Axel Le Cesne, Andrea Varga, Rastilav Bahleda, Andrew J. Wagner, Edwin Choy, Maja J. de Jonge, Madelyn Light, Steve Rowley, Sandrine Macé, James Watters

Get full text

Extraskeletal Myxoid Chondrosarcoma: Clinical and Molecular Characteristics and Outcomes of Patients Treated at Two Institutions by Benedetta Chiusole, Axel Le Cesne, Marco Rastrelli, Marco Maruzzo, Martina Lorenzi, Rocco Cappellesso, Paolo Del Fiore, Silvia Imbevaro, Marta Sbaraglia, Philippe Terrier, Pietro Ruggieri, Angelo Paolo Dei Tos, Carlo Riccardo Rossi, Carlo Riccardo Rossi, Vittorina Zagonel, Antonella Brunello

Get full text

EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib. by Olivier Bouché, Axel Le Cesne, Maria Rios, Loic Chaigneau, Antoine Italiano, Florence Duffaud, Thierry Lecomte, Dominique Arsène, Sylvain Manfredi, Thomas Aparicio, Stéphane Remy, Nicolas Isambert, Olivier Collard, Frank Priou, François Bertucci, Roland Sambuc, Ségolene Bisot-Locard, Olivier Bourges, Sylvie Chabaud, Jean-Yves Blay

Get full text